1173 / 1578
/
•
For many combinations, NO data available
Concerns of increased toxicity:
Drug
SRT location Toxicity
Cetuximab
Head and neck
Mucositis, dermatitis, fistula
Sorafenib
Abdomen
Bleeding, bowel obstruction
Gefitinib, Erlotinib Thoracic
Pneumonitis
Bevacizumab
Abdominal
Ulcer, perforation
BRAF inhibitors Brain
Hemorrhage
07.09.17
ESTRO SBRT COURSE 2017 - Matthias Guckenberger
43
Systematic review: SRT & targeted drugs
/
DEGRO AG Stereotaxie Project: TOaSST
Register Study of concomitant use of SRT and
targeted drugs
Eligibility criteria:
• Treatment of
any metastatic tumor
with
•
Stereotactic radiotherapy
• and any
targeted drug
(antibodies, small molecules,
immunotherapy)
• within
+ / - 4 weeks
prior and after SBRT
Primary endpoint:
• High grade toxicity > grade II
Secondary endpoints:
• OS, LC, DFS
07.09.17
ESTRO SBRT COURSE 2017 - Matthias Guckenberger
44